Gastric cancer's Japanese death toll makes latest Opdivo nod a big one

22 September 2017
2019_biotech_test_vial_discovery_big

With the leading pair of immuno-oncology (I-O) agents Keytruda (pembrolizumab) and Opdivo (nivolumab) seemingly scoring new approvals by the month in major markets, it would be easy to ignore the importance of the latest nod for the latter drug in Japan.

Opdivo, which is being jointly developed and commercialized in the Asian country by US pharma major Bristol-Myers Squibb (NYSE: BMY) and Japan’s Ono Pharmaceutical (TYO: 4528), has been approved by Japan’s Ministry of Health, Labor and Welfare for the treatment of unresectable advanced or recurrent gastric cancer which has progressed after chemotherapy.

"Gastric cancer took approximately 50,000 lives in Japan last year"

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology